Revolution in addiction therapy: Spraying alcohol consumption dramatic!

Revolution in addiction therapy: Spraying alcohol consumption dramatic!

The current study by Markku Lähteenvuo at the University of East Finland shows promising results for patients with alcohol addiction who receive the weight loss injection Semaglutid and Liraglutid. These drugs, known as Ozempic and Wegovy or Victoza and Saxenda, lead to reduced alcohol consumption for users and reduce the risk of hospital stays. The examination that analyzed health data from 227,000 alcohol -dependent fins, showed that Semaglutid reduces the risk by impressive 36 percent and liraglutid by 28 percent, which is significant progress compared to other forms of therapy such as Naltrexon, which only offers a risk reduction of 14 percent. These results could open up new treatment approaches for the estimates of 340,000 alcohol addicts in Austria, where the consumption carries health risks, such as kosmo.at

alcohol addiction in Germany

The situation is not only worrying in Austria. In Germany, around 3 million adults between the ages of 18 and 64 suffer from alcohol -related disorders. This comprises 1.4 million people with alcohol abuse and 1.6 million with alcohol addiction. Another alarming result shows that 7.9 million people in this age group consume alcohol in health -risky amounts. These figures illustrate the urgency of new treatment methods in view of the high alcohol consumption and the associated health problems, as dhs.de detailed.

The knowledge of the study from Finland could not only advance medical research in relation to weight loss injections, but also contribute to the development of new treatment options in order to counteract the increasing number of alcohol -dependent people. Doctors and researchers are therefore excited about future developments that may be influenced by further clinical studies that could confirm the effectiveness of these medication.